Investors Buy Alexion Pharmaceuticals, Inc. (ALXN) on Weakness

Investors bought shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on weakness during trading hours on Wednesday. $63.04 million flowed into the stock on the tick-up and $35.59 million flowed out of the stock on the tick-down, for a money net flow of $27.45 million into the stock. Of all companies tracked, Alexion Pharmaceuticals had the 27th highest net in-flow for the day. Alexion Pharmaceuticals traded down ($0.45) for the day and closed at $107.60

ALXN has been the subject of several recent analyst reports. Zacks Investment Research cut shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, November 1st. Royal Bank Of Canada boosted their price objective on shares of Alexion Pharmaceuticals to $166.00 in a research note on Tuesday, October 24th. Piper Jaffray Companies reissued an “overweight” rating and set a $170.00 price objective on shares of Alexion Pharmaceuticals in a research note on Monday, October 23rd. Stifel Nicolaus lowered their price objective on shares of Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating for the company in a research note on Tuesday, October 24th. Finally, Leerink Swann boosted their price objective on shares of Alexion Pharmaceuticals from $136.00 to $170.00 and gave the company an “outperform” rating in a research note on Friday, July 28th. Six investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $154.01.

The company has a debt-to-equity ratio of 0.35, a current ratio of 2.96 and a quick ratio of 2.51. The firm has a market capitalization of $24,040.00, a price-to-earnings ratio of 22.19, a P/E/G ratio of 1.18 and a beta of 1.22.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, topping analysts’ consensus estimates of $1.32 by $0.12. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The firm had revenue of $859.00 million for the quarter, compared to analyst estimates of $864.34 million. During the same quarter in the previous year, the business posted $1.23 EPS. The firm’s revenue was up 7.5% compared to the same quarter last year. sell-side analysts expect that Alexion Pharmaceuticals, Inc. will post 4.81 earnings per share for the current year.

In other news, Director Ann M. Veneman sold 835 shares of the company’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total value of $121,751.35. Following the sale, the director now owns 5,480 shares in the company, valued at approximately $799,038.80. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Julie O’neill sold 11,160 shares of the company’s stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $140.00, for a total transaction of $1,562,400.00. Following the completion of the sale, the executive vice president now owns 26,704 shares in the company, valued at approximately $3,738,560. The disclosure for this sale can be found here. In the last 90 days, insiders sold 16,490 shares of company stock worth $2,337,251. Company insiders own 4.35% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. Rathbone Brothers plc raised its stake in shares of Alexion Pharmaceuticals by 2.5% in the 2nd quarter. Rathbone Brothers plc now owns 2,040 shares of the biopharmaceutical company’s stock valued at $248,000 after purchasing an additional 50 shares in the last quarter. Seven Bridges Advisors LLC raised its stake in shares of Alexion Pharmaceuticals by 2.1% in the 2nd quarter. Seven Bridges Advisors LLC now owns 2,638 shares of the biopharmaceutical company’s stock valued at $321,000 after purchasing an additional 53 shares in the last quarter. Geneva Advisors LLC raised its stake in shares of Alexion Pharmaceuticals by 0.7% in the 2nd quarter. Geneva Advisors LLC now owns 11,408 shares of the biopharmaceutical company’s stock valued at $1,388,000 after purchasing an additional 82 shares in the last quarter. Grandfield & Dodd LLC raised its stake in shares of Alexion Pharmaceuticals by 2.8% in the 2nd quarter. Grandfield & Dodd LLC now owns 3,360 shares of the biopharmaceutical company’s stock valued at $409,000 after purchasing an additional 90 shares in the last quarter. Finally, Evercore Wealth Management LLC raised its stake in shares of Alexion Pharmaceuticals by 8.1% in the 2nd quarter. Evercore Wealth Management LLC now owns 1,665 shares of the biopharmaceutical company’s stock valued at $202,000 after purchasing an additional 125 shares in the last quarter. Institutional investors and hedge funds own 95.80% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://ledgergazette.com/2017/11/22/investors-buy-alexion-pharmaceuticals-inc-alxn-on-weakness.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply